CP 117227

• CAT Number: I006199
• CAS Number: 154531-78-9
• Molecular Formula: C31H33N3O2
• Molecular Weight: 479.61
• Purity: ≥95%
• Synonyms: CP 117227; CP-117227; CP117227.;1-Piperazineethanol, 4-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-alpha-((5-quinolinyloxy)methyl)-, (S)-
• Target: MDR Modulator
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term ,or -20 °C for long term
• IUPAC Name: (2S)-1-quinolin-5-yloxy-3-[4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)piperazin-1-yl]propan-2-ol
• InChI: InChI=1S/C31H33N3O2/c35-25(22-36-30-13-5-12-29-28(30)11-6-16-32-29)21-33-17-19-34(20-18-33)31-26-9-3-1-7-23(26)14-15-24-8-2-4-10-27(24)31/h1-13,16,25,31,35H,14-15,17-22H2/t25-/m0/s1
• InChIKey: YLQSXCMKFKBZLE-VWLOTQADSA-N
• SMILES: C1CC2=CC=CC=C2C(C3=CC=CC=C31)N4CCN(CC4)C[C@@H](COC5=CC=CC6=C5C=CC=N6)O

CP 117227（Cat No.:I006199）is a selective and potent antagonist of the NK1 (neurokinin-1) receptor, which is involved in mediating pain, inflammation, and neurogenic responses, particularly through the neuropeptide substance P. By blocking this receptor, CP 117227 has been explored for its potential to alleviate conditions associated with excessive substance P release, such as chronic pain, anxiety, and nausea. It has been investigated in preclinical and clinical studies for its efficacy in treating pain disorders, including those related to cancer and chemotherapy-induced nausea. Further research is needed to assess its long-term safety and therapeutic potential.